SynthesisBrain and behavior2025
Genetic Basis of the Negative Response to the Use of Triptans for the Treatment of Migraine-A Systematic Review and Meta-Analysis.
Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Genetic Basis of the Negative Response to the Use of Triptans for the Treatment of Migraine-A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMigraine is a widespread and disabling neurological disorder, and triptans are a primary treatment for acute episodes. However, around 40% of patients are non-responsive. Genetic polymorphisms can influence drug effectiveness, and several association studies exist. This systematic review consolidates findings from etiological studies, which may provide greater certainty about their use in predicting the risk of low response to triptans.
methodThis study followed COSMOS-E guidelines and employed databases like PubMed, Web of Science, and Embase until 2023. The Newcastle-Ottawa Scale (NOS) was used to assess quality, and statistical meta-analysis was performed.
resultsA comprehensive literature search identified 1421 articles from which 30 met eligibility for full-text review, and 9 studies were included in the final analysis. Although the overall analysis did not confirm a statistically significant association, subgroup analyses demonstrated significant relationships between SLC6A4, 5-HT1B, and COMT polymorphisms and triptan nonresponse, while CALCA and PRDM16 had moderate evidence, and GRIA1 and SCN1A polymorphisms exhibited limited evidence for non-response. While our analysis revealed that genetic polymorphisms are an essential cause of heterogeneity in response to triptans, the included studies showed substantial variability and methodological inconsistency. Polygenic risk scores (PRS) and combined genetic approaches, including prospective clinical trials and multi‑omics integration, can help stratify triptan nonresponders and inform decision‑making in precision and personalized medicine (PPM).
conclusionsThese results underscore the potential utility of these genetic associations in tailored migraine therapy and reinforce the involvement of serotonergic and dopaminergic pathways in triptan efficacy. Future studies with larger and more homogeneous cohorts are essential to validate these associations. Still, clinical implementation of polygenic risk score (PRS) may offer a more effective pathway for applying PPM in migraine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.